Mammography Clinical Trial
— MICROENHANCEOfficial title:
Can Contrast Enhanced Spectral Mammography (CESM) Reduce the Number of Benign Biopsies for Calcifications Without Negatively Impacting on Detection/Diagnosis of Clinically Significant Calcifications
Women who attend for their screening mammogram will be recalled if an abnormality is detected on the screening mammogram. Calcifications account for 20% of the women recalled to second stage screening. Currently there is no effective imaging tool to determine if the calcifications are cancer or not. Therefore, 90% of women will be subjected to a biopsy. 25-30% of the biopsies will show cancer. Contrast enhanced spectral mammography (CESM) is where contrast is given and then a mammogram performed. The theory is that high risk DCIS and invasive cancers have an increased blood supply and will therefore enhance more than benign lesions within the breast. If CESM can identify calcifications that are cancerous then we maybe able to reduce the number of women who have benign biopsies. This is patient focused as women would not require a biopsy and be able to be reassured at the same visit. This is also a cost-saving for the Trust by reducing unnecessary biopsies. This also supports the findings of the Marmot review by aiming to reduce harm by over-diagnosis.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | February 2, 2021 |
Est. primary completion date | February 2, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 50 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Recalled for second stage screening due to microcalcifications on the mammogram 2. Renal function is within normal limits 3. No known allergies to contrast 4. Able to give informed consent Exclusion Criteria: 1. Known allergy to contrast 2. Renal impairment 3. Unable to provide informed consent 4. Having radioactive iodine treatment for hyperthyroidism |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds |
Lead Sponsor | Collaborator |
---|---|
The Leeds Teaching Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of benign biopsies | Total number of benign biopsies identified whilst undergoing CESM. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04983875 -
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
|
N/A | |
Recruiting |
NCT04904757 -
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
|
N/A | |
Recruiting |
NCT05975736 -
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
|
N/A | |
Withdrawn |
NCT03639129 -
Improving Characterization of Calcifications With Contrast-Enhanced Mammography
|
N/A | |
Completed |
NCT03684733 -
Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer
|
||
Completed |
NCT00827307 -
Zoladex Plus Tamoxifen in Breast Cancer
|
N/A | |
Completed |
NCT00724516 -
Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography
|
N/A | |
Not yet recruiting |
NCT06469606 -
Study on Female Patients' Mammographic Texture Features
|
N/A | |
Completed |
NCT04009278 -
Self-compression Mammography in Clinical Practice
|
N/A | |
Completed |
NCT01124019 -
Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
|
||
Recruiting |
NCT05199701 -
Prospective Case Collection Study for New Mammography Technologies
|
N/A | |
Recruiting |
NCT05009277 -
Study To Evaluate The Sensitivity Of The Linda Thermal Device
|
||
Completed |
NCT04741503 -
Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool
|
N/A | |
Not yet recruiting |
NCT06265207 -
The Effect of Virtual Reality on Pain, Anxiety and Satisfaction Level Before Mammography
|
N/A |